Watching Sutro Biopharma; Traders Circulate FDA Orphan Drug Designation For ‘Treatment of pediatric acute myeloid leukemia’
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=915722
Sutro Biopharma Q3 EPS $(0.37) Up From $(0.67) YoY
Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(0.37) per share. This is a 44.78 percent increase over losses of $(0.67) per share from the same period last year.
Sutro Biopharma Earnings Perspective: Return On Capital Employed
According to data from Benzinga Pro, during Q2, Sutro Biopharma's (NASDAQ:STRO) reported sales totaled $28.10 million. Despite a 33.49% increase in earnings, the company posted a loss of $26.01 million.
Truist Securities Maintains Buy on Sutro Biopharma, Lowers Price Target to $21
Truist Securities analyst Asthika Goonewardene maintains Sutro Biopharma (NASDAQ:STRO) with a Buy and lowers the price target from $37 to $21.
Recap: Sutro Biopharma Q2 Earnings
Sutro Biopharma (NASDAQ:STRO) reported its Q2 earnings results on Monday, August 8, 2022 at 04:30 PM.
Here's what investors need to know about the announcement.